Psioxus Therapeutics Limited

Pfizer Vaccines, Lcc

Akamis Bio Limited

Brian Robert Champion

Alice Claire Noel Brown

David Michael Wyatt

Alice Claire Noel Bromley

Kerry David Fisher

Alan Daniel Brown

Lee Richard Roberts

Lyn Howard Jones

David Cameron Pryde

Brian Gregory Pierce

Xiayang Qiu

Julie Jia Li Hawkins

Tamara Nicolson

James Richard Merson

Michael Dale Eisenbraun

David Paul Gervais

Leonard Gabriel Contillo, Jr

Anne Maria Kristina Kjerrstrom

James Downey Fraser

Jakir Hussain Ullah

Leonard William Seymour

David Robert Stead

Paul Andrew Wright

Clare Christy

Joshua David Freedman

Leonard Charles William Seymour

Clare Lees

Matthieu Besneux

Mathieu Besneux

Jr Leonard Gabriel Contillo

Alice Claire Brown

Claire Noel Bromley Alice

A modified adenovirus, in particular Enadenotucirev (EnAd), armed with at least two bispecific T cell engagers each comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on an immune cell of interest, such as a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.

Adenovirus armed with bispecific T cell engager

A modified adenovirus, in particular Enadenotucirev (EnAd), armed with a bispecific T cell activator comprising at least two binding domains, wherein at least one of the domains is specific for a surface antigen on a T-cell of interest. Also provided are a composition, such as a pharmaceutical formulation comprising the virus, use of the virus and virus formulations for treatment, such as in the treatment of cancer. The disclosure also extends to processes for preparing the virus.

Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager

The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic adenovirus selected from the group consisting of Ad11 and enadenotucirev, wherein the virus encodes an antibody or a binding fragment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), wherein the virus does not encode a B7 protein or an active fragment thereof, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.

Group B adenovirus encoding an anti-TCR-complex antibody or fragment

The present disclosure relates to a group B adenovirus comprising a sequence of formula (I):

Oncolytic adenoviruses armed with heterologous genes

An adenovirus comprising a sequence of formula (I) 5'ITR-B-B-B-B-B-B-B-3&#x2032;ITR wherein Bcomprises a transgene cassette containing four transgenes, said genes encoding a FAP-Bispecific T cell activator, CXL10, CXL9, and IFN. The disclosure also extends to a pharmaceutical composition comprising the virus, and use of the virus or formulation in treatment.

Adenovirus armed with bispecific T cell activator

The present disclosure relates to a replication deficient oncolytic viral vector or replication capable oncolytic virus encoding an antibody or a binding fragment thereof to the antigen-specific T-cell receptor complex (TCR) for expression on the surface of a cancer cell, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer.

Virus encoding an anti-TCR-complex antibody or fragment

An oncolytic virus (for example a replication competent virus) comprising a transgene cassette encoding an anti-CD40 antibody or binding fragment thereof, wherein the transgene cassette comprises an amino acid sequence given in SEQ ID NO: 12 or a sequence at least 95% identical thereto (such as 96, 97, 98 or 99% identical thereto), in particular a cassette of SEQ ID NO: 12; pharmaceutical compositions comprising the same, methods of preparing said oncolytic virus and compositions and use of the oncolytic virus or composition in treatment, in particular in the treatment of cancer. Also provided is the treatment of a patient population characterised as having a cancer expressing CD40, in particular a cancer over expressing CD40, with a therapy according to the present disclosure.

Oncolytic virus and method

The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.

Oncolytic adenovirus encoding a B7 protein

Oncolytic adenovirus encoding a B7 protein or active fragment

The present disclosure provides a oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a membrane anchored anti-CD3 antibody or a binding fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.

Oncolytic adenovirus encoding a therapeutic protein or active fragment

The present disclosure relates to a type B adenovirus wherein E4orf4 is deleted or non-functional and generally having a DNA sequence in the E3 region, in particular viruses of formula (I), compositions containing the virus, for example pharmaceutical formulations of the virus, processes for making the viruses and the compositions and use of any one of the same in treatment, particularly in the treatment of cancer, such as colorectal cancer and ovarian cancer.5'ITR-B-B-B-B-B-B-B-3&#x2032;ITR&#x2003;&#x2003;(I).

Group B adenovirus modified in the E4orf4 region

The present disclosure relates to a group B adenovirus comprising a sequence of formula (I): 5'ITR-B1-BAB2-BX-BB-BY-B3-3&#x2032;ITR wherein: B1 is bond or comprises: E1A, E1B or E1AE1B; BA comprises: E2B-L1-L2-L3-E2A-L4; B2 is a bond or comprises: E3; BX is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; BB comprises L5; BY is a bond or a DNA sequence comprising: a restriction site, one or more transgenes or both; B3 is a bond or comprises: E4; wherein at least one of BX or BY is not a bond, pharmaceutical compositions comprising the same and use of the viruses and compositions in treatment, particularly in the treatment of cancer. The disclosure also extends to plasmids and processes employed to prepare the said viruses.

Growing community of inventors

Abingdon, United Kingdom

Brian Robert Champion